Kyverna Q2: net loss $38.3M ($0.63/share); RMAT for miv-cel in naSPMS; SPS BLA on track for Q4 2026

Kyverna Therapeutics, Inc.

Cash, equivalents and marketable securities $199.4M at June 30, 2026; operating runway into 2028.
Q2 2026 R&D expenses $24.8M; G&A expenses $14.8M; net loss $38.3M or $0.63 per share.
FDA granted RMAT designation for miv-cel in non-active secondary progressive MS (naSPMS) based on IIT data from Stanford and UCSF.
Rolling BLA for miv-cel in stiff person syndrome underway; CMC module submitted; completion targeted Q4 2026 with priority review and potential 2027 launch.
KYSA-6 Phase 3 gMG enrollment expected complete mid-2027; KYSA-8 12-month and Phase 2 gMG follow-up topline data expected Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.